

The Diminishing Role of Aspirin in Managing Cardiovascular Disease: Journal Supplement to *The American Journal of Cardiology*



Evaluation

Please visit <https://academiccme.com/AJC-Supplement> to review and complete the evaluation portion of this activity and download your CE certificate.

Learning Objectives

1. Review the mechanism of action of aspirin in cardiovascular disease, its specific effects on the platelet and intravascular inflammation, and the impact of those effects on efficacy and safety outcomes.
2. Describe the evolution of outcomes evaluations, safety assessments, and trial design, that has led to new perspectives on aspirin in cardiovascular disease.
3. Review in detail the latest data on aspirin for primary prevention in cardiovascular disease.
4. Review the most recent guidelines recommendations and underlying data regarding the use of aspirin in patients with atrial fibrillation who undergo percutaneous coronary intervention.
5. Explain the latest clinical trials and data regarding withdrawal of aspirin from a dual antiplatelet therapy in selected patients without atrial fibrillation who undergo percutaneous coronary intervention.
6. Describe potential new formulations, delivery methods, and therapeutic targets of aspirin currently in development.

Faculty

Chair

Charles V. Pollack Jr., MA, MD, FACEP, FAHA, FACC, FESC

Clinician-Scientist

Department of Emergency Medicine

University of Mississippi School of Medicine

Jackson, Mississippi

Faculty

Tom Adriaenssens, MD, PhD

Department of Cardiovascular Diseases

University Hospitals

Leuven, Belgium

Dominick J. Angiolillo, MD, PhD

Division of Cardiology

University of Florida College of Medicine

Jacksonville, FL

Juan J. Badimon, PhD

AtheroThrombosis Research Unit

Mount Sinai Heart

Icahn School of Medicine at Mount Sinai

Mount Sinai Hospital

New York City, NY

Deepak L. Bhatt, MD, MPH

Executive Director of Interventional Cardiovascular Programs

Brigham and Women's Hospital Heart & Vascular Center

Professor of Medicine, Harvard Medical School

Boston, Massachusetts

Christopher Cannon, MD

Cardiovascular Division, Brigham and Women's Hospital

Harvard Medical School

Boston, MA

Davide Capodanno, MD, PhD

Division of Cardiology

A.O.U. "Policlinico-Vittorio Emanuele,"

University of Catania

Catania, Italy

Carlos G. Santos-Gallego, MD

Postdoctoral Fellow, Cardiology

Icahn School of Medicine at Mount Sinai

Mount Sinai Hospital

New York City, NY

Peter Sinnaeve, MD

Department of Cardiovascular Medicine

University Hospitals Leuven

Department of Cardiovascular Sciences

University of Leuven

Leuven, Belgium

Tracy Y. Wang, MD, MHS, MSc

Duke Clinical Research Institute

Duke University

Durham, NC

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty	Relationship Identified With:
Charles V. Pollack Jr., MA, MD	Consulting fees or honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, PhaseBio, Provepharm, Milestone, and eXIthera. Research support from AstraZeneca, Provepharm, eXIthera, Janssen Pharma, CSL/Behring, Daiichi-Sankyo, and Portola.
Tom Adriaenssens, MD	<i>Speaker's Bureau:</i> AstraZeneca; Sanofi; Daiichi Sankyo; Boehringer <i>Grant/Research Support:</i> Amgen; AstraZeneca; Bayer; Biosensors; Celonova; CSL Behring; Daiichi-Sankyo; Eisai; Eli Lilly; Gilead; Idorsia; Janssen; Matsutani Chemical Industry Co.; Merck; Novartis; Osprey Medical; Renal Gland Solutions
Dominick J. Angiolillo, MD	<i>Consultant/Advisor:</i> Abbott; Amgen; Aralez; AstraZeneca; Bayer; Biosensors; Boehringer Ingelheim Bristol-Myers Squibb; Chiesi; Daiichi-Sankyo; Eli Lilly; Haemonetics; Janssen; Merck; PhaseBio; PLx Pharma; Pfizer; Sanofi; The Medicines Company
Juan J. Badimon, PhD	<i>Nothing to disclose</i>
Deepak Bhatt, MD, MPH	<i>Grant/Research Support:</i> Abbott; Afimmune Limited; Amarin Corporation; Amgen Inc.; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim International GmbH; Bristol Myers Squibb Company; Cardax, Inc.; Chiesi USA, Inc.; CSL Behring; Eli Lilly and Company; Eisai Co., Ltd.; Ethicon Inc.; Ferring Pharmaceuticals; Forest Laboratories; Fractyl Laboratories, Inc.; Idorsia Pharmaceuticals Ltd; Ironwood Pharmaceuticals, Inc.; Ischemix; Lexicon; Medtronic; Pfizer Inc.; PhaseBio Pharmaceuticals; PLx Pharma Inc.; Regeneron Pharmaceuticals Inc.; Roche; Sanofi; Synaptic; The Medicines Company
Christopher Cannon, MD	<i>Grant/Research Support:</i> Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Janssen; Merck; Pfizer
Davide Capodanno, MD	<i>Speaker's Bureau:</i> AstraZeneca; Bayer; Sanofi Aventis; Boehringer Ingelheim; Daiichi Sankyo
Carlos G. Santos-Gallego, MD	<i>Nothing to disclose</i>
Peter Sinnaeve, MD	<i>Speaker's Bureau:</i> AstraZeneca; Sanofi; Daiichi Sankyo; Boehringer
Tracy Y. Wang, MD, MHS, MSc	<i>Grant/Research Support:</i> Abbott; AstraZeneca; Bristol-Myers Squibb; Boston Scientific; Cryolife; Chiesi; Merck; Portola; Regeneron

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin; and Emma Boring hereby state

that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement



JOINT ACCREDITATION
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements

AcademicCME designates this enduring material for a maximum of 8.00 *AMA PRA Category 1 Credits*TM.

AcademicCME designates this enduring material for a maximum of 8.0 CNE Contact Hours, including 8.0 pharmacotherapeutic contact hours (Provider number P0491).

AcademicCME designates this continuing education activity for 8.0 CPE Contact Hours (0.80 CEU) of continuing pharmacy education credit (UAN # JA4008190-0000-20-021-H04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participation completion information to ACCME for the purpose of granting ABIM MOC credit.

The accreditation period for this program is March 15, 2021 through March 31, 2022.

Financial Support

This activity has been supported by an independent educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and AstraZeneca Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Review the Journal Supplement content.
3. Visit: <https://academiccme.com/AJC-Supplement> to complete the Post-Activity Test Questions and Evaluation.
4. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
 - CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
 - CME and CNE credit will be issued appropriate certificate of completion.
 - Others may request a "certificate of completion".
5. Learners should claim only the credit commensurate with the extent of their participation in the activity

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact admin@academiccme.com.